Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa)

Antiviral Therapy

Volumn 10, Issue 7, 2005, Pages 855-859

  Maslin, Jérôme ^a   Rogier, Christophe ^b   Caron, Melanie ^a   Grandadam, Marc ^a   Koeck, Jean Louis ^c   Nicand, Elisabeth ^a  

^a University of Paris Descartes   (France)

^b SERVICE DE SANTÉ DES ARMÉES   (France)

^c HÔPITAL D'INSTRUCTION DES ARMÉES ROBERT PICQUÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CLINICAL ARTICLE; DJIBOUTI; FEMALE; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; MUTATION RATE; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; VIRUS MUTATION; VIRUS TRANSMISSION; ADULT; ARTICLE; CLASSIFICATION; DRUG EFFECT; GENETICS; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DJIBOUTI; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 27844602337     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Kantor R & Katzenstein D. Polymorphism in HIV-1 non subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Reviews 2003; 5:25-35.
2. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM & Shafer RW. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PloS Med 2005; 2(4):e112.
3. Maslin J, Rogier C, Berger F, Khamil MA, Mattera D, Grandadam M, Caron M & Nicand E. Epidemiology and genetic characterization of HIV-1 isolates in the general population of djibouti (Horn of Africa). JAIDS 2005; 39:129-132.
4. United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update, December 2004. Geneva, Switzerland [cited 2005 Oct 12]. Available from: http://www.unaids.org/wad2004/EPIupdate2004_html_en/e pi04_00_en.htm
5. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A & Richman D. Update of the drug resistance mutations in HIV-1: 2005. Topics in HIV Medicine 2005; 13:51-57.
6. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: recommendations for a public health approach (2005 revision). Geneva, Switzerland [cited 2005 Oct 12]. Available from: http://www.womenchildrenhiv. org/wchiv?page=wx-resource&rid=20255&topic=chl&type=prgd
7. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J & Delaporte E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. The Journal of Cardiovascular Management 2000; 38:3919-3925.
8. Descamps D, Apetrei C, Collin G, Damond F, Simon F & Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111.
9. th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, USA. Abstract K-41.
10. Handema R, Terunuma H, Kasolo F, Kasai H, Sichone M, Yamashita A, Deng X, Mulundu G, Ichiyama K, Munkanta M, Yokota T, Wakasugi N, Tezuka F, Yamamoto N & Ito M. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Research and Human Retroviruses 2003; 19:151-160.
11. Koch N, Ndihokubwayo JB, Yahi N, Tourres C, Fantini J & Tamalet C. Genetic analysis of HIV type 1 strains in Bujumbura (Burundi): predominance of subtype C variant. AIDS Research and Human Retroviruses 2001; 17:269-273.
12. Clavel F & Hance AJ. HIV drug resistance. The New England Journal of Medicine 2004; 10:1023-1035.
13. Winston A, Mandalia S, Pillay D, Gazzard B & Pozniak A. The prevalence and determinants of the K65R mutations in HIV-1 reverse transcriptase in tenofovir-naïve patients. AIDS 2002; 16:2087-2089.
14. Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, Daar ES, D'Aquila RT, Keiser PH, Connick E, Hellmann NS, Petropoulos CJ, Richman DD & Little SJ. Reduced susceptibility of human immunodeficiency virus type 1 from patients with primary HIV infection to non nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. Journal of Virology 2000; 74:10269-10273.
15. Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Chureeratana B, Pacharee K, Pranee L, Ariyadej S, Leenasirimakul P, Hammer S & Lallemant M. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. The New England Journal of Medicine 2004; 351:229-238.
16. Perrin V & Mammano F. Parameters driving the selection of nelfinavir-resistant HIV-1 variants. XII International HIV Drug Resistance Workshop. 10-14 June 2003, Los cabos, Mexico. Abstract 50.
17. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP & Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.